The new European Union (EU) medical device regulation (MDR) and in vitro diagnostic regulation (IVDR), originally published in 2017, sets forth more stringent requirements for medical device and in vitro diagnostic manufacturers that distribute products in the EU.
These regulations, which will replace decades old legislation, require manufacturers to make significant changes in product development, data reporting and quality assurance.
With expanded clinical evidence requirements and increased regulatory requirements, the transition to comply with these directives can be challenging. To complicate the process further, there will be no grandfathering of legacy devices, which are defined as products covered by certificates issued in accordance with the outgoing directives but placed on the market after the new regulations take effect. These devices are subject to most of the incoming regulatory requirements, but carry a set of unique considerations.
To help manufacturers navigate this, The European Commission has published guidance on the management and registration of legacy devices in the EUDAMED database. Here we summarise the key points of the guidance, including identification requirements for legacy devices, when manufacturers need to register devices on EUDAMED and how to link products covered by the outgoing and incoming regulatory frameworks.
Identification requirements under MDR/IVDR
Once made compliant with MDR/IVDR, legacy devices will have to follow MDR/IVDR registration requirements with the EUDAMED database in case a serious incident occurs or there is a field safety corrective action to apply. However, these devices may not necessarily have to be assigned Basic UDI-DI and UDI-DI codes, which are the primary identifiers of each unique device.
For example, in some instances, legacy devices have already been assigned UD-DI codes prior to implementation of the new regulations, which may be used for EUDAMED registration and identification purposes. In this case, the EUDAMED DI is automatically generated from the existing UDI-DI value. The Legacy Device will therefore have the following identification elements:
- A UDI-DI (assigned by the manufacturer)
- A EUDAMED DI (generated based on the UDI-DI)
Implementation of the EUDAMED database will be conducted in phases, launched in May 2021. The target date to complete applications is set for May 2022.
Linking the regulation devices to legacy devices
The EUDAMED database supports the linking of new devices with legacy devices and their successors. If a MDR/IVDR compliance device is exactly the same as the legacy device, the products may share the same UDI-DI. As such, linking will occur automatically based on UD-DI information upon registration with EUDAMED. If the products are not identical aside from MDR/IVDR compliance or no UDI-DI has been pre-assigned, the manufacturer will need to provide the legacy device identifier to manually link the products.
Additional considerations
If an equivalent device is not made compliant and registered as a MDR or IVDR device within 18 months after the date of MDR/IVDR application, the legacy device must be registered in EUDAMED. Moreover, legacy devices falling within risk class I that are not sterile cannot be considered as legacy devices because they do not require a certificate issued by a Notified Body. Instead, these devices must be registered only as regulation devices in EUDAMED within the 18 months after the date of application.
ICON’s Medical Device and Diagnostics Research team has over 30 years of clinical development & commercialisation service experience with medical device and IVD companies.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel